×

Genomind Announces New Portal at NEI Global Psychopharmacology Congress

SAN DIEGO, Oct. 18, 2012 (GLOBE NEWSWIRE) -- Genomind, a personalized medicine company for neuropsychiatry, is excited to announce its new clinician online portal at the Neuroscience Education Institute (NEI) Global Psychopharmacology Congress in San Diego. Genomind will host a Product Theater at the Congress on Saturday, October 20, 2012 at 7 am, where co-founder and Chief Scientific Officer Dr. Jay Lombard will discuss the Company's Genecept Assay, introduce attendees to the new system, and showcase the convenient features for clinicians.

The portal is a secure, convenient way for clinicians to easily access their patients' test results from the Genecept Assay. The Assay is Genomind's comprehensive, saliva-based test, which looks at genes and biomarkers that may affect the type of medication or treatment a clinician would prescribe to patients suffering from difficult-to-treat psychiatric disorders. The secure site allows clinicians to review and download comprehensive reports via login credentials any time or place, giving flexibility to their busy schedules. All results will be available electronically and can be downloaded directly from the portal. The portal also allows easy access to peer-reviewed study data related to genes in the panel.

The portal is also the home of Genomind's innovative Open Label Study, which measures the real world use and impact of the Genecept Assay on patient treatment and outcomes. The study has a unique design to enable timely, efficient reporting online for clinicians and patients.

The portal will be accessible on the Genomind website homepage or via email alerts sent to clinicians once their patients test results are live and available.

The Neuroscience Education Institute Annual Conference runs from October 18-21, 2012, at the Manchester Grand Hyatt in San Diego. In addition to the Product Theater, Genomind will be available on the main show floor at Booth 115 to share more information about the portal, the Genecept Assay, and their dedication to harnessing the latest research to better treat patients.

About the Genecept™ Assay

The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind's core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/products/assay.

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients' lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

For more information, contact:

Doreen Korba
Director of Marketing
215.396.5596
Doreen.Korba@genomind.com

This information was brought to you by Cision http://www.cisionwire.com
http://www.cisionwire.com/genomind/r/genomind-announces-new-portal-at-nei-global-psychopharmacology-congress,c9320528

Source: Genomind